Joseph G. Crompton, MD, PhD

Joseph G. Crompton, MD, PhD

Assistant Professor, Department of Surgery, Surgical Oncology





Surgical Oncology, Memorial Sloan-Kettering Cancer Center, 2020
Surgical Oncology, National Cancer Institute, 2015


PhD, University of Cambridge, England, 2016
MD, Johns Hopkins School of Medicine, Baltimore, MD, 2009
BA, University of Wisconsin, Madison, WI, 2003


General Surgery, UCLA School of Medicine, 2018

Board Certification

Surgery, American Board of Surgery, 2019

Contact Information

Scientific Interests

Dr. Joseph Crompton is a surgeon-scientist with a primary clinical focus on the multimodality treatment of melanoma and soft tissue sarcoma. His current research interests include characterizing the immune response to cancer and developing novel immunotherapies for the treatment of advanced disease.

Highlighted Publications

Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics. Crompton JG, Sukumar M, Roychoudhuri R, Clever D, Gros A, Eil RL, Tran E, Hanada K, Yu Z, Palmer DC, Kerkar SP, Michalek RD, Upham T, Leonardi A, Acquavella N, Wang E, Marincola FM, Gattinoni L, Muranski P, Sundrud MS, Klebanoff CA, Rosenberg SA, Fearon DT, Restifo NP.Cancer Res. 2015 Jan 15;75(2):296-305. doi: 10.1158/0008-5472.CAN-14-2277. Epub 2014 Nov 28.PMID: 25432172

Lineage relationship of CD8(+) T cell subsets is revealed by progressive changes in the epigenetic landscape. Crompton JG, Narayanan M, Cuddapah S, Roychoudhuri R, Ji Y, Yang W, Patel SJ, Sukumar M, Palmer DC, Peng W, Wang E, Marincola FM, Klebanoff CA, Zhao K, Tsang JS, Gattinoni L, Restifo NP.Cell Mol Immunol. 2016 Jul;13(4):502-13. doi: 10.1038/cmi.2015.32. Epub 2015 Apr 27.PMID: 25914936

Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy. Klebanoff CA, Crompton JG, Leonardi AJ, Yamamoto TN, Chandran SS, Eil RL, Sukumar M, Vodnala SK, Hu J, Ji Y, Clever D, Black MA, Gurusamy D, Kruhlak MJ, Jin P, Stroncek DF, Gattinoni L, Feldman SA, Restifo NP.JCI Insight. 2017 Dec 7;2(23):e95103. doi: 10.1172/jci.insight.95103.PMID: 29212954

Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy. Klebanoff CA, Scott CD, Leonardi AJ, Yamamoto TN, Cruz AC, Ouyang C, Ramaswamy M, Roychoudhuri R, Ji Y, Eil RL, Sukumar M, Crompton JG, Palmer DC, Borman ZA, Clever D, Thomas SK, Patel S, Yu Z, Muranski P, Liu H, Wang E, Marincola FM, Gros A, Gattinoni L, Rosenberg SA, Siegel RM, Restifo NP.J Clin Invest. 2016 Jan;126(1):318-34. doi: 10.1172/JCI81217. Epub 2015 Dec 14.PMID: 26657860

Targeting Akt in cell transfer immunotherapy for cancer. Crompton JG, Sukumar M, Restifo NP.Oncoimmunology. 2015 Dec 29;5(9):e1014776. doi: 10.1080/2162402X.2015.1014776. eCollection 2016.PMID: 27757294